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INTRODUCTION
Signal propagation between cardiomyocytes is a very tightly
regulated system. Mutations in ion channels involved in this system
can cause electrical alterations that, in certain circumstances, such
as during exercise or emotional stress, could trigger arrhythmias.
Sudden death in a young healthy person can be the first devastating
presentation of an underlying genetic disease. Long QT syndrome
(LQTS) can either be genetic or acquired (e.g. drug-induced) in
nature and is due to defective functioning of cardiac ion channels.
LQTS is characterized by a prolonged cardiac repolarization phase
resulting in a long QT interval in the surface electrocardiogram
(ECG). The clinical symptoms of LQTS include palpitations,
syncope, seizures and even sudden cardiac death. A special type
of polymorphic ventricular tachycardia [torsade de pointes (TdP)]
is associated with LQTS. Intriguingly, many mutation carriers are
without any symptoms. A total of 12 congenital LQTS subtypes
are presently known (Hedley et al., 2009). Two of these subtypes
account for more than 90% of all genetically identified LQTS cases
and both are due to defective functioning of potassium channels.
LQTS type 1 (LQT1) is the most common subtype, resulting from
mutations in the KCNQ1 gene, which encodes the -subunit of the
slow component of the delayed rectifier potassium current (IKs)
channel (Chiang and Roden, 2000). Individuals with LQT1 typically
have symptoms during exercise (Schwartz, 2001; Roden, 2008).
LQTS type 2 (LQT2) is due to defective functioning of the -
subunit of the rapid delayed potassium channel (IKr), encoded by
the KCNH2 [also known as human ether-a-go-go-related gene
(HERG)] gene (Curran et al., 1995). Typically, individuals with LQT2
have clinical symptoms after abrupt auditory stimuli, often during
sleep when the heart rate is slow (Schwartz, 2001; Roden, 2008).
The acquired form of LQTS is also due to altered functioning of
the same KCNH2 ion channel.
Induced pluripotent stem cell (iPSC) technology (Takahashi et
al., 2007; Yu et al., 2007) has revolutionized research on genetic
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SUMMARY
Long QT syndrome (LQTS) is caused by functional alterations in cardiac ion channels and is associated with prolonged cardiac repolarization time
and increased risk of ventricular arrhythmias. Inherited type 2 LQTS (LQT2) and drug-induced LQTS both result from altered function of the hERG
channel. We investigated whether the electrophysiological characteristics of LQT2 can be recapitulated in vitro using induced pluripotent stem cell
(iPSC) technology. Spontaneously beating cardiomyocytes were differentiated from two iPSC lines derived from an individual with LQT2 carrying
the R176W mutation in the KCNH2 (HERG) gene. The individual had been asymptomatic except for occasional palpitations, but his sister and father
had died suddenly at an early age. Electrophysiological properties of LQT2-specific cardiomyocytes were studied using microelectrode array and
patch-clamp, and were compared with those of cardiomyocytes derived from control cells. The action potential duration of LQT2-specific
cardiomyocytes was significantly longer than that of control cardiomyocytes, and the rapid delayed potassium channel (IKr) density of the LQT2
cardiomyocytes was significantly reduced. Additionally, LQT2-derived cardiac cells were more sensitive than controls to potentially arrhythmogenic
drugs, including sotalol, and demonstrated arrhythmogenic electrical activity. Consistent with clinical observations, the LQT2 cardiomyocytes
demonstrated a more pronounced inverse correlation between the beating rate and repolarization time compared with control cells. Prolonged
action potential is present in LQT2-specific cardiomyocytes derived from a mutation carrier and arrhythmias can be triggered by a commonly used
drug. Thus, the iPSC-derived, disease-specific cardiomyocytes could serve as an important platform to study pathophysiological mechanisms and
drug sensitivity in LQT2.
Model for long QT syndrome type 2 using human iPS
cells demonstrates arrhythmogenic characteristics in
cell culture
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diseases. iPSCs can be generated from somatic cells of any
individual and these pluripotent cells can be differentiated into the
desired cell type. Accordingly, it is possible to create genotype-
specific cell models with a correct functional intracellular
environment. However, a major challenge in the iPSC approach is
to reproduce the phenotype of the disease or the individual in iPSC-
derived cells. An appropriate disease phenotype has been
reproduced with iPSC technology from individuals with LQT1
(Moretti et al., 2010), LQT2 (Itzhaki et al., 2011; Matsa et al., 2011)
and with Timothy syndrome (Yazawa et al., 2011). Considering non-
cardiac disorders, a disease phenotype or pathogenesis in iPSC-
derived models has been demonstrated only for a few neurological
diseases (Lee and Studer, 2010) and for the LEOPARD syndrome
(Carvajal-Vergara et al., 2010).
The penetrance of the clinical symptoms of LQTS is low and
there is considerable variation in phenotypic expression even
within families carrying the same mutation (Priori et al., 1999). In
addition, it has been proposed that the population prevalence of
milder LQTS mutations might be high, suggesting that the
prevalence of latent or concealed LQTS, i.e. relatively asymptomatic
individuals, is higher than currently anticipated (Marjamaa et al.,
2009). For these reasons, LQTS is clinically very challenging. The
previous LQT2 iPSC reports used individuals with severe
symptoms and the severity of their symptoms was translated to the
cardiomyocytes derived from the patient-specific iPSCs. However,
a cell model for asymptomatic LQT2 mutation carriers would be
valuable to help with clinical decisions about medical treatments
and lifestyle restrictions for relatively asymptomatic patients.
A more thorough understanding of the molecular mechanisms
underlying LQTS would be very helpful for the pharmaceutical
industry. Drug-induced forms of LQTS often arise as a result of
inhibition of the hERG channel gating, and is thus analogous to
LQT2 (Hancox et al., 2008). These adverse cardiac effects have led
to labeling restrictions on both cardiac and non-cardiac drugs as
well as to withdrawal from the market (Roden, 2004). Currently,
preclinical testing of new chemical entities (NCEs) for
proarrhythmic potential relies on animal experiments and ectopic
expression of individual ion channels in non-cardiac cells (Pollard
et al., 2008). However, current models lack the relevant human
physiological environment that might regulate or modify cellular
responses (Pollard et al., 2008). Thus, some NCEs could be
unnecessarily discarded in the preclinical phase, and others already
in clinical use might in fact elicit adverse cardiac side effects.
Functional cardiomyocytes derived from both symptomatic and,
possibly even more importantly, asymptomatic LQTS individuals
would add to and complement presently used models. These cell
models would provide the relevant cellular milieu to study genetic
and non-genetic interactions influencing the phenotype.
In the present study, we developed an in vitro cell model of LQT2.
In contrast to the previous reports (Itzhaki et al., 2011; Matsa et
al., 2011), we aimed at generating a model from cells of an
individual with LQT2 without severe symptoms. To that end, iPSC
lines were derived from a patient’s fibroblasts carrying a mutation
for LQT2. Although there is a family history of overt LQTS, this
individual was asymptomatic except for occasional palpitations and
his 12-lead ECG exhibited a heart-rate-corrected QT time (QTc)
of 437 ms. This model for LQT2 provides an important platform
to study the pathophysiology of LQT2 and to evaluate adverse




A skin biopsy was obtained from a 61-year-old man with a missense
mutation in KCNH2 causing an arginine-to-tryptophan
substitution at position 176 (R176W, hERG-FinB; Fig. 1A).
Although there is a family history of overt LQTS, this individual
was asymptomatic except for occasional palpitations. His 12-lead
ECG exhibited a QTc of 437 ms (Fig. 1B). His sister was diagnosed
with LQTS having a QT(U)c interval of 550 ms (Fig. 1C), presence
of palpitations and sudden death at the age of 32.
Characterization of iPSCs
Fibroblasts from an individual with LQT2 were infected with
retroviruses encoding for OCT4, SOX2, KLF4 and MYC to generate
iPSCs. Morphologically, iPSC colonies exhibited characteristics
similar to those of human embryonic stem cells (hESCs), with
rounded shape and clear defined edges (Fig. 2A). Both LQT2-
specific iPSC lines (UTA.00514.LQT2 and UTA.00525.LQT2) and
control iPSC lines expressed endogenous pluripotent markers at
the mRNA level, as shown by reverse transcriptase PCR (RT-PCR)
(Fig. 2B). The protein expression of pluripotency genes was also
demonstrated by immunocytochemical stainings (Fig. 2C) for
further confirmation. By contrast, exogenous gene expression was
turned off in all iPSC lines by passage six (Fig. 2B). Exogenous gene
expression was not detected after cardiac differentiation,
demonstrating that these genes were not reactivated in the process
(data not shown). The generated iPSC lines were also analyzed for
their karyotypes, which were all normal (Fig. 2D).
To confirm the pluripotency of our iPSC lines, an embryoid body
(EB) formation assay was performed. The EB-derived cells from
LQT2 iPSC and control iPSC lines all expressed markers from the
three different embryonic lineages: endoderm, ectoderm and
mesoderm (Fig. 2F). Pluripotency of the lines was further confirmed
by teratoma formation. Teratomas were made from one LQT2-
specific line (UTA.00525.LQT2) and two control lines
(UTA.00112.hFF and UTA.01006.WT). In every case, tissues from
all three germ layers were found in the teratomas (Fig. 2E).
Fig. 1. Mutation and ECG analysis. (A)Mutation analysis confirmed the hERG-
FinB mutation in the LQT2 iPSC line, which gave altered DNA cleavage by the
SmaI restriction enzyme (lower arrow). (B,C)ECG from leads V1-V3 of the index
patient, with a QTc of 437 ms (B), and from the patient’s sister, with the
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Cardiomyocyte differentiation and characterization
LQT2-specific iPSCs, control iPSCs and hESCs differentiated into
spontaneously beating cells. As shown by RT-PCR, these
differentiated control and LQT2 cardiomyocytes expressed cardiac
markers: troponin T (TNTT2), ventricular myosin light chain
(MLC2V), atrial myosin light chain (MLC2A), connexin-43 (Cx-
43), myosin heavy chain b (MHC-b; MYH7), HERG and GATA4
(Fig. 3B). The expression of cardiac troponin T, -actinin and Cx-
43 was also seen at the protein level as evidenced in Fig. 3A. The
electrical properties of iPSC- and hESC-derived cardiomyocytes
were also studied using microelectrode array (MEA; Fig. 3C,D).
There were differences between control and LQT2-specific cells
Fig. 2. Characterization of
iPSCs. (A)Morphology of the
iPSC colonies is similar to those
of hESCs. The colonies are rather
roundish and the edges are well
defined and sharp, which is
typical for a stem cell colony.
(B)Expression of pluripotency
markers in LQT2-specific iPSCs is
shown by RT-PCR. All the
endogenous pluripotency genes
studied were turned on in iPSCs
by passage 6 (top panel). As a
positive control, they were also
expressed in hESCs (H7).
Expression of Sox2 and very
modest expression of Rex1 and
Myc was found also in EBs,
which were used as a negative
control. b-actin served as a
loading control. None of the
exogenous genes were
expressed in iPSCs at passage
11. As a positive control, PCR
was also done using the
transfected plasmids as
templates (bottom panel). RT-
PCR results were similar for all
the iPSC lines.
(C)Immunocytochemical
staining of the cells shows that
pluripotency markers are
expressed also at the protein
level. The expression of Nanog,
Oct3/4, Sox2, SSEA-4, TRA1-60
and TRA1-81 was similar in all
iPSC lines and there were no
differences between LQT2-
specific and control lines.
(D)Karyotypes of all the iPSC
lines were analyzed and proved
to be normal. (E)Teratomas were
made from one LQT2-specific
line and two control lines to
further confirm the pluripotency
of the lines. Tissues from all
three germ layers were found in
teratomas from every line.
(F)EBs were also formed from all
the lines to show the
pluripotent differentiation
capacity. The EB-derived cells
from both LQT2-iPSC and all
control iPSC lines expressed
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in their field potential durations (FPDs) (Fig. 3C), but both types
showed increased chronotrophy when treated with isoprenaline, a
b-adrenergic agonist (Fig. 3D), which is the anticipated response
and indicates intact b-adrenergic signaling.
Electrophysiological properties of differentiated cardiomyocytes
The differentiation of both control and LQT2-specific iPSCs into
cardiomyocyte subtypes was evident from the morphology of the
spontaneous action potentials (APs) recorded with the patch-clamp
technique. Two types of AP morphology were observed: ventricular-
like, which displayed a distinct plateau phase; and atrial-like, which
were triangular shaped (Fig. 4A). The AP properties of control-iPSC-
derived cardiomyocytes were similar to those of other human ESC
and iPSC studies (Table 1) (Gai et al., 2009; Yokoo et al., 2009; Zwi
et al., 2009). For most AP parameters there was no significant
difference between control and LQT2-iPSC-derived cardiomyocytes
(P>0.05; Table 1). However, ventricular-like LQT2-iPSC-derived
cardiomyocytes had significantly prolonged AP durations at 50% and
90% repolarization (APD50 and APD90, respectively). The APD50 and
APD90 of atrial-like LQT2-iPSC-derived cardiomyocytes, although
prolonged, did not reach statistical significance. On the borderline
of statistical significance was the slower AP frequency of ventricular-
Fig. 3. The expression of cardiac markers in iPSC-derived cardiomyocytes
and the electrical properties of the cells. (A)Immunocytochemical staining
of different cardiac markers: troponin T and -actinin are shown in red; green
indicates connexin-43 and blue represents DAPI-staining for nuclei. The
expression was similar in LQT2-specific and control cells, and there were no
line-specific differences in the expression of cardiac proteins. (B)The
expression of a larger repertoire of cardiac markers was also studied, with RT-
PCR showing that the iPSC-derived cardiac cells manifest cardiac properties.
TNTT2, MLC2V, MLC2A, Cx-43, MYH7, GATA4 and HERG were present in the cells
at the mRNA level. (C)Electrical properties of the cells were studied with MEA,
which revealed the differences between LQT2-specific and control cells. FPD
was significantly longer in LQT2-specific cardiomyocytes than in control
cardiac cells. However, all lines evince the typical electrical properties of
cardiomyocytes. (D)LQT2-specific cardiomyocytes showed increased
chronotrophy when challenged with isoprenaline, a b-adrenergic agonist.
Fig. 4. Current-clamp recordings from human iPSC-derived
cardiomyocytes. (A)Spontaneous APs from healthy control iPSC-derived
(upper APs) and LQT2 patient-derived (lower APs) cardiomyocytes. The dashed
line denotes 0 mV. (B)The action potential duration (APD) measured at 50%
and 90% repolarization from the AP peak (APD50 and APD90) of spontaneous
atrial-like (n5-6) and ventricular-like APs. For the latter, both the APD50 and
APD90 of LQT2 patient-derived cardiomyocytes (n13) were significantly
prolonged compared with those of hESCs (n7) or control-iPSC origin (n11).
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like LQT2-iPSC-derived cardiomyocytes; therefore, further analysis
was restricted to a subset of cardiomyocytes to reduce the effect of
any rate-dependent APD adaptation.
Both the APD50 and APD90 of LQT2-iPSC-derived ventricular-
like cardiomyocytes were significantly prolonged compared with
control-iPSC- and hESC-derived cardiomyocytes (P<0.001; Fig.
4A,B), at an AP frequency of about 1 Hz (P0.13 between groups).
The APD90 was 516.5±26.1 ms in LQT2-specific cardiomyocytes
compared with 310.5±19.6 ms in control-iPSC-derived
cardiomyocytes or 338.6±19.9 ms in hESC-derived cardiomyocytes.
The APD90 did not differ significantly between cardiomyocytes
from the two LQT2 iPSC lines (UTA.00514.LQT2 and
UTA.00525.LQT2) or between hESC-derived cardiomyocytes and
those of control iPSC origin. Collectively, these data indicate that
the LQT2-iPSC-derived cardiomyocytes express the disease
phenotype, characterized by a prolonged cardiac repolarization
phase. Spontaneous arrhythmogenic activity was rare, early after
depolarizations (EADs) were observed in only one of 20 LQT2-
iPSC-derived cardiomyocytes studied (Fig. 4C) and in no recordings
from control iPSC cardiomyocytes (n20).
Ventricular-like cardiomyocytes were subjected to further
investigations using voltage clamp (Fig. 5). Using the specific inhibitor
E-4031, IKr was isolated (Fig. 5A) and its magnitude shown to be
markedly reduced in LQT2 iPSC cardiomyocytes compared with that
in control iPSC cardiomyocytes (Fig. 5B). Tail IKr density was
significantly decreased, by 40-46%, after a depolarizing step to
voltages from 0 to +40 mV (P<0.01; Fig. 5C). A similar reduction in
tail IKr density (~40%) was seen in experiments when an alternative
method, isotonic cesium conditions (Zhang, 2006), was used to isolate
IKr from a different control and LQT2 iPSC line (supplementary
Table 1. AP properties of atrial- and ventricular-like cardiomyocytes
No. cells Frequency (Hz) APD50 (ms) APD90 (ms)
dV/dtmax
(V/second) APA (mV) MDP (mV)
Atrial-like
Control 6 1.8±0.1 116.7±8.4 157.7±11.0 9.2±0.5 104.4±1.3 –65.6±0.6
LQT2 5 1.4±0.1 156.0±25.0 210.9±33.3 11.7±1.6 105.0±2.7 –65.4±1.4
Ventricular-like
Control 13 1.2±0.1 264.7±15.0 314.4±17.6 26.8±6.3 113.2±2.4 –63.4±1.3
LQT2 16 0.9±0.1a 455.3±26.7b 538.0±28.5b 15.8±0.7 117.3±1.4 –62.4±0.9
AP properties of spontaneously beating human iPSC-derived cardiomyocytes. dV/dtmax, maximum rise of the AP upstroke; APA, AP amplitude; MDP, maximum diastolic potential.
Mean values ± s.e.m. are shown. Comparison of control iPSC-CMs and LQT2 iPSC-CMs groups was performed with unpaired t-test with P<0.05 considered statistically significant.
aP=0.05; bP<0.000005. CMs, cardiomyocytes.
Fig. 5. IKr recorded from iPSC cardiomyocytes with a ventricular-like AP. (A)Example of the isolation of IKr. Whole-cell current, here from a control iPS
cardiomyocyte, was recorded in the absence (a) and then presence of 1mol/l E-4031 (b), with IKr defined as the subtracted current (a-b), i.e. the E-4031-sensitive
current. Current was evoked by a 5-second depolarization from a holding potential of –40 mV as shown in the inset. (B)IKr of a control iPS (black) and LQT2 iPS
(red) cardiomyocyte evoked as in A with the time segment between the arrows expanded to show the peak tail currents on return to –40 mV following a step to
+20 mV. (C)The peak tail IKr densities of control iPSC (black; n4) and LQT2 iPSC (red; n5) cardiomyocytes at membrane potentials from 0 to +40 mV were
significantly different (*P<0.01, **P<0.005). (D)IKr currents of control iPSC (black) and LQT2 iPSC (red) cardiomyocytes evoked by a voltage protocol of step to +20
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material Fig. S1). The reduction in resurgent IKr during repolarization
was also demonstrated with the use of a step-ramp voltage protocol
as a simplified version of a cardiac AP (Fig. 5D).
The in vitro cardiac FPD on MEA has been shown to correlate
with QT interval properties in the ECG, and FPD recordings of
beating cell aggregates give insight into the electrical function of
myocardial tissue in vitro (Caspi et al., 2008). We observed a
negative correlation between FPD and beating rate both in control
cardiomyocytes and LQT2-specific cardiomyocytes (Fig. 6A,B).
However, the LQT2 cardiomyocytes had a significantly prolonged
FPD compared with controls, especially at low beating frequencies
(P0.014; Fig. 6A,B), as determined by nonlinear regression
analysis. The two LQT2 iPSC lines behaved the same way and,
thus, their data were combined, as were data from the three
different control iPSC lines and hESC-derived cardiomyocytes,
because they behaved similarly.
The inotropic response of the iPSC-derived cardiac cells was
studied using isoprenaline. A panel of drugs with known QT-
prolongation effects, including erythromycin, sotalol and cisapride,
and a non-drug compound, E-4031, were investigated. The selective
hERG blocker E-4031 increased arrhythmogenicity in control
cardiac cells and even more frequently in LQT2 cardiomyocytes
(Fig. 6C). Application of sotalol (0.8-19.4 mol/l), an anti-
arrhythmic drug with both b-blocker and class III activity, elicited
arrhythmogenicity at the highest tested concentrations only in
LQT2 cardiac cells (Fig. 6C). No increased arrhythmogenicity was
observed with erythromycin (1.5-16 mol/l) or cisapride (40-330
nmol/l) in control or LQT2 cardiac cells (data not shown). At
baseline, no arrhythmogenicity was observed with control or LQT2
cardiac cells on MEA.
DISCUSSION
In this study we demonstrate that patient-specific iPSCs can be
used to model a potentially lethal cardiac arrhythmic disease in
vitro. The cells were differentiated into functional cardiomyocytes,
which reproduced the phenotypic characteristics of LQT2,
including a prolonged repolarization time and increased
arrhythmogenicity. Furthermore, at slow beating rates, FPD (QT)
was significantly more prolonged in LQT2 cardiomyocytes
compared with control cells.
Fig. 6. FPD measured on MEA. (A)The effect of the beating rate on FPD in control and LQT2 cardiomyocytes (CMs). Control and LQT2 cardiomyocytes had a
negative correlation with moderately high coefficients of determination (R2). The exponential function gave the best fit as determined by R2 between different
fitting functions. The LQT2 cardiomyocytes had significantly more prolonged FPD compared with controls, especially at low beating frequencies, as determined
by nonlinear regression analysis (P0.0136). (B)At beating rates below 50 beats per minute (bpm), the FPD of LQT2 cardiomyocytes differed significantly from
control cardiomyocytes (*P<0.05) as determined by t-test. (C)Drug responses of control and LQT2 cardiomyocytes. Sotalol (19mol/l) and E-4031 (500 nmol/l for
LQT2-specific cells and 700 nmol/l for control cells) was administered to the cardiomyocyte aggregates derived from control iPSCs and LQT2 iPSCs. For both cell
lines, baseline and drug conditions for sotalol and E-4031 are shown. Arrows mark the site of pharmacologically induced EADs. With 500 nmol/l E-4031 there
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The R176W hERG mutation was reported to have the frequency
of 0.5% in apparently healthy individuals (Ackerman et al., 2003)
and, according to an epidemiological Finnish study, the mutation
is present in about one of 400 Finns (Marjamaa et al., 2009). The
majority of these individuals are completely asymptomatic and
unaware of their carrier status. This mutation is one of the four
founder mutations for LQTS in Finland and these mutations
account for almost two-thirds of all established LQTS cases in the
country (Fodstad et al., 2004). The QTc interval of LQT2 patients
with the R176W mutation is reported to range from 386 to 569
ms, with a mean of 448 ms, whereas the mean for non-carriers was
416 ms (Fodstad et al., 2006). Furthermore, the mutation has also
been identified in cases of sudden death (Tester and Ackerman,
2007; Tu et al., 2011). Although our patient had latent LQTS, his
family did not. His younger sister died suddenly at the age of 32
when awakened by a telephone and his father died suddenly at the
age of 40. The sister was documented to have abnormal QT
intervals of up to 582 ms. The symptoms in this family, including
palpitations, syncope, and sudden death due to abrupt auditory
stimuli during sleep, were typical of LQT2 (Schwartz, 2001; Roden,
2008). In our study, the repolarization time was significantly
prolonged in cultured LQT2-specific cardiac cells, compared with
control cells, at low beating rates, and this is consistent with the
clinical observation that, at slow beating rate, the QT interval is
prolonged more in LQT2 patients compared with healthy
individuals (Swan et al., 1999).
Although the underlying mechanism of R176W is presently
unknown, when heterologously expressed, R176W reduces hERG
tail current density by ~75%, although upon coexpression with wild
type the difference in current densities was nullified (Fodstad et
al., 2006). The decrease of ~43% in IKr density observed here in iPS
cardiomyocytes from a heterozygous R176W individual might
reflect the difference in cellular environment, e.g. the composition
of the endogenous IKr channel, which includes both the ubiquitously
in vitro expressed hERG1a subunit and hERG1b subunit with its
alternatively spliced N-terminus, presence of accessory subunits
and/or native interactions. However, it is also possible that this
observed discrepancy results from a differential expression of the
wild-type and mutant alleles in vitro versus in vivo. In both model
systems, R176W does not display a dominant-negative effect,
unlike the A614V hERG mutation (Nakajima et al., 1998). iPS cell
lines with that particular mutation derived from a severely
symptomatic LQT2 patient with recorded TdP have been generated
(Itzhaki et al., 2011). This mutation resulted in a decrease in the
activating IKr density of 72% with a depolarization step to 0 mV
and of 64% in the tail current density following depolarization to
+20 mV. Smaller reductions in these values (43% and 40%,
respectively) were obtained for the R176W hERG mutation here.
This difference in IKr reduction translates to the APD: at 1 Hz the
ventricular-like LQT2 iPSC cardiomyocyte APD90 was 166% and
~200% of control for R176W and A614V, respectively, and in
arrhythmogenicity, with EADs rarely observed here (~5%) but
frequently (66%) in the report by Itzhaki and coworkers. Thus, the
in vitro results obtained with iPSC cardiomyocytes seems to
correspond to differences in expression of the disease, i.e. latent
versus overt LQTS. Similarly, Matsa et al. demonstrated that the
APD of both atrial-like and ventricular-like iPSC cardiomyocytes
was significantly prolonged when derived from an LQT2 patient
with episodes of syncope, seizures and TdP (Matsa et al., 2011).
Although, in the study by Matsa et al., no spontaneous
arrhythmicity was observed, such an effect could be induced
pharmaceutically by isoprenalin.
One explanation for the genotype-phenotype discordance in
LQTS is the repolarization reserve. This concept proposes that
redundant mechanisms are available to bring about normal
repolarization; therefore, to elicit the full-blown LQTS phenotype
multiple hits might be required to sufficiently reduce the reserve
(Roden, 2006). Such ‘hits’ might be the presence of compound
mutations, polymorphisms, drug exposure, female gender,
hypokalemia or other risk factors (Roden, 2006; Lehtonen et al.,
2007). Evidence for the repolarization reserve and its genetic
modulation comes from studies of individuals or first-degree
relatives of individuals with drug-induced LQTS showing a
prolongation of repolarization indices with pharmacological
challenge (Kannankeril et al., 2005; Couderc et al., 2009). The
unmasking of latent LQTS can occur accidentally (e.g. associated
drug-induced TdP) (Lehtonen et al., 2007). In line with the
repolarization reserve hypothesis and the clinical data, R176W
LQT2 cardiac cells were more sensitive to drug effects that controls.
The hERG-channel-specific blocker E-4031 induced
arrhythmogenicity in both control and LQT2 cardiac cells, but
sotalol induced arrhythmogenic behavior only in LQT2 cardiac
cells. Sotalol has been used as a pharmacological challenge and is
documented as inducing TdP in a patient carrying a hERG channel
mutation (Lehtonen et al., 2007; Couderc et al., 2009). The
concentrations of sotalol used in this study are similar to the
effective free therapeutic plasma concentration range (1.8-14.7
mol/l) (Redfern et al., 2003). Sotalol probably exacerbates the
underlying defect, because the potency of sotalol towards hERG is
similar between wild type and variant in transfected cells
(Männikkö et al., 2010).
Comparison of single-cell recordings and MEA analysis and ECG
findings of the patients revealed an interesting observation. Although
single-cell recordings indicated major differences in repolarization
time between control- and LQT2-derived cardiac cells (66% increase
in AP90 in LQT2 cardiomyocytes), the corresponding differences
measured using cell aggregates with the MEA technique were much
more moderate (10-20%) and resembled differences in ECG in
healthy individuals and LQTS patients (Fodstad et al., 2006). Similar
observations can be found in the previously reported iPSC studies
on LQTS. AP90 duration was reported to be increased by 50% in
LQT1 cardiac cells compared with control cells, whereas the
difference in ECG was only in the range of 10-15% (Moretti et al.,
2010). In the studies with LQT2 cells, the repolarization times were
greatly prolonged already at ECG level (50% or more) and similar
differences were observed in their MEA recordings (50% difference
between control and LQT2 cardiac cells) (Itzhaki et al., 2011; Matsa
et al., 2011). However, in both of these studies, the AP90 duration
was increased by 2- to 2.5-fold compared with control repolarization
time. It is possible that cell-to-cell contacts in the syncytium result
in compensatory mechanisms with a tendency to protect the
repolarization system from major deviation from the normal
conditions.
Our results on the abnormal electrophysiological properties and
increased drug sensitivity of cardiac cells derived from an
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issue about LQT2 and also a new challenge, as well as a possibility,
for the pharmaceutical industry. LQT2 cell models for severely
symptomatic patients (Itzhaki et al., 2011; Matsa et al., 2011) are
most useful for studying the pathology of LQT2 and demonstrate
in a convincing way that the phenotype of this syndrome can be
reproduced in a cell culture model. Our results complement the
previous research on LQT2-specific iPSC-derived cardiomyocytes
by introducing a cell model for an asymptomatic mutation carrier.
According to our findings, even these clinically asymptomatic
individuals can possess the inherent electrophysiological
abnormality in their cardiac cells. Taking advantage of this large
resource of Finnish individuals with the same mutation, it might
be possible to evaluate the electrophysiological properties and drug
responses of cardiomyocytes from mutation carriers with and
without symptoms, and thereby try to identify putative genetic or
non-genetic modifiers of LQTS. These types of studies might also
assist in the tailoring of individualized drug treatment of these
patients. In the future, iPSC technology is likely to be increasingly
exploited for drug development and safety studies.
In conclusion, iPSC-derived cardiomyocytes from an individual
with LQT2 displayed the disease cardiac phenotype in cell culture
conditions even though the individual was relatively asymptomatic.
This model provides an additional platform to study the basic
pathology of LQTS and to individualize drug treatment in a
patient-specific manner. It also provides the means to explore the
differences between clinical patients and mutation carriers and to
scan the cardiac effects of different drugs on both.
METHODS
The study was approved by the ethical committee of Pirkanmaa
Hospital District (R07080).
Cell culture
The LQT2 cells were derived from a 61-year-old man with an
R176W mutation of KCNH2 (hERG-FinB) (Fodstad et al., 2004).
Primary fibroblasts from a skin biopsy were cultured under
fibroblast culturing conditions: Dulbecco’s Modified Eagle’s
Medium (DMEM) (Lonza, Basel, Switzerland) containing 10% fetal
bovine serum (FBS) (Lonza), 2 mmol/l L-glutamine, 50 U/ml
penicillin/streptomycin. 293FT cells (Invitrogen, Carlsbad, CA)
were maintained similarly with 1% non-essential amino acids
(NEAA) (Cambrex, East Rutherford, NJ). Plat-E (Cell Biolabs, San
Diego, CA), irradiated SNL-76/7 (HPA Culture Collections,
Salisbury, UK) and mouse embryonic fibroblast (MEF; Millipore,
Billerica, MA) cells were cultured without antibiotics. iPSCs and
hESCs were maintained in KSR medium: knockout (KO)-DMEM
(Invitrogen) containing 20% KO serum replacement (KO-SR,
Invitrogen), NEAA, L-glutamine, penicillin/streptomycin, 0.1
mmol/l 2-mercaptoethanol and 4 ng/ml basic fibroblast growth
factor (bFGF; R&D Systems, Minneapolis, MN). H7 hESCs (WiCell
Research Institute, Madison, WI) and iPSC lines FiPS 6-14 and
UTA.00112.hFF (derived from foreskin fibroblasts),
UTA.01006.WT and UTA.04602.WT (from adult skin fibroblasts)
were used as controls.
Generation of iPSC lines
Patient-specific iPSC lines were established using lentivirus infection
followed by retrovirus infection into the primary fibroblasts. The
following cells, plasmids and reagents were used: 293FT cells, Plat-
E cells, pLenti6/UbC/mSlc7a1 vector (Addgene, Cambridge, MA),
ViraPower Packaging Mix (Invitrogen), Lipofectamine 2000
(Invitrogen), pMX retroviral vector (hOCT3/4, hSOX2, hKLF4 or
hc-MYC; Addgene) and Fugene 6 (Roche Diagnostics, Mannheim,
Germany). The protocol used has been described previously
(Takahashi et al., 2007). Two LQT2-specific lines were established
(UTA.00514.LQT2 and UTA.00525.LQT2) carrying the R176W
mutation, which was confirmed by PCR as described previously
(Fodstad et al., 2006). The FiPS 6-14 line was derived at the University
of Helsinki (provided by Timo Otonkoski) (Rajala et al., 2010). Control
iPSC lines from healthy individuals (UTA.01006.WT from a 36-year-
old male and UTA.04602.WT from a 55-year-old female) and the
UTA.00112.hFF line from human foreskin fibroblasts were
established in the same way as the LQT2 lines.
RT-PCR
Total RNA was collected from the iPSC lines at passages 3, 6 and
11 and after cardiac differentiation. For positive pluripotency
control, the H7 line was used. RNA from EBs was used as a negative
control of pluripotency. RNA was purified with NucleoSpin RNA
II kit (Macherey-Nagel, Düren, Germany) and cDNA conversion
was performed with a high-capacity cDNA RT kit (Applied
Biosystems, Carlsbad, CA). PCR was done with Dynazyme II
(Finnzymes Oy, Espoo, Finland) using 1 l of cDNA as a template
and 2 M primers. As positive controls for exogenous primers, PCR
was also done using the transfected plasmids (hOCT3/4, hSOX2,
hKLF4 and hc-MYC) as templates. PCR primers for iPSC
characterization and detailed reaction conditions have been
described previously (Takahashi et al., 2007). Primers for different
germ layers and cardiac markers are presented in Table 2. b-actin
and GAPDH were used as housekeeping controls.
Immunocytochemistry for pluripotency
iPSCs at passage 8 were fixed with 4% paraformaldehyde (Sigma-
Aldrich) and stained with anti-OCT3/4 (1:400; R&D Systems), anti-
tumor-related antigen (TRA)1-60 (1:200; Millipore), anti-SOX2,
anti-NANOG, anti-stage-specific embryonic antigen (SSEA)4 and
anti-TRA1-81 (all 1:200; from Santa Cruz Biotechnology, Santa




EBs were cultured without feeder cells in EB medium (KO-DMEM
with 20% FBS, NEAA, L-glutamine and penicillin/streptomycin)
without bFGF for 5 weeks. RNA isolation and reverse transcription
from EBs was performed as described above. The expression of
markers characteristic of ectoderm, endoderm and mesoderm
development in EBs was determined using RT-PCR (primers
described in Table 2).
Mutation analysis
The hERG-FinB mutation was assayed with restriction enzyme
analysis (Fodstad et al., 2006) by amplifying the genomic DNA with
primers for hERG (forward: 5-ACCACGTGCCTCTCCTCTC-3,
reverse: 5-GTCGGGGTTGAGGCTGTG-3) (reagents from
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SmaI digestion enzyme (Fermentas GmbH, St Leon-Rot, Germany).
The hERG-FinB mutation resulted in deletion of a SmaI-cleavage
site. SmaI-cleaved PCR products were detected with gel
electrophoresis: products for wild type were 182, 79, 46 and 23 bp
and for R176W heterozygote 182, 125, 79, 46 and 23 bp long.
Karyotype analysis
Karyotypes of the cell lines were defined using standard G-banding
chromosome analysis by a commercial company (Medix
Laboratories, Espoo, Finland) according to standard procedure.
Teratoma formation
iPSCs were injected into nude mice under the testis capsule. Tumor
samples were collected 8 weeks after injection and fixed with 4%
paraformaldehyde. The sections were stained with hematoxylin and
eosin.
Cardiac differentiation and characterization
Cardiomyocyte differentiation was carried out by co-culturing
iPSCs and H7 hESCs with END-2 cells (a kind gift from Christine
Mummery, Hubrecht Institute, Utrecht, The Netherlands). END-
2 cells were cultured as described earlier (Mummery et al., 2003).
The beating areas of the cell colonies were mechanically excised
and treated with collagenase A (Roche Diagnostics) as described
previously (Mummery et al., 2003). Seven days after dissociation,
cells were fixed with 4% paraformaldehyde for immunostaining with
anti-cardiac-troponin-T (1:2000; Abcam, Cambridge, MA), anti-
-actinin (1:1500; Sigma-Aldrich, St Louis, MO) and anti-connexin-
43 (1:1000; Sigma-Aldrich).
Patch-clamp technique
APs were recorded from spontaneously beating dissociated cells
using the perforated patch (by amphotericin) configuration of the
patch-clamp technique with an Axopatch 200B amplifier
(Molecular Devices, Sunnyvale, CA). A coverslip with the adhered
cells was placed in the recording chamber and perfused with
extracellular solution consisting of (in mmol/l) 143 NaCl, 4 KCl,
1.8 CaCl2, 1.2 MgCl2, 5 glucose, 10 HEPES (pH 7.4 with NaOH;
osmolarity adjusted to 301±3 mOsm). Patch pipettes were pulled
from borosilicate glass capillaries (Harvard Apparatus, Kent, UK)
and had resistances of 1.5-3.5 MΩ when filled with a solution
consisting of (in mmol/l): 122 K-gluconate, 30 KCl, 1 MgCl2, 5
HEPES (pH 7.2 with KOH; osmolarity adjusted to 290±3 mOsm).
The final concentration of amphotericin B (solubilized in
dimethylsulfoxide) in the pipette was 0.24 mg/ml.
The data was filtered at 2 kHz, and digitized (Digidata 1322A;
Molecular Devices) at 10 kHz; data acquisition and analysis was
performed with pClamp 9.2 software (Molecular Devices). For some
cardiomyocytes, voltage-clamp experiments were also performed
to record IKr. Experiments were conducted at 36±1°C.
Field potential recordings
Field potentials of spontaneously beating cardiomyocyte aggregates
were recorded with the MEA platform (Multi Channel Systems,
Reutlingen, Germany) at 37°C. MEAs were hydrophilized with FBS
for 30 minutes, washed with sterile water and coated with 0.1%
gelatin for 1 hour. Cardiomyocyte aggregates were plated onto
MEAs in EB medium. FPD and beating frequency were determined
manually with AxoScope software (Molecular Devices).
Table 2. Primers for RT-PCR of different germ layer markers and cardiac markers.
Gene Primer F (5 -3 ) Primer R (5 -3 ) Size (bp)
Endodermal markers
AFP AGAACCTGTCACAAGCTGTG GACAGCAAGCTGAGGATGTC 672
SOX17 CGCACGGAATTTGAACAGTA CACACGTCAGGATAGTTGCAG 166
Mesodermal markers
-cardiactin GGAGTTATGGTGGGTATGGGTC AGTGGTGACAAAGGAGTAGCCA 486
KDR GTGACCAACATGGAGTCGTG TGCTTCACAGAAGACCATGC 218
Ectodermal markers
SOX1 AAAGTCAAAACGAGGCGAGA AAGTGCTTGGACCTGCCTTA 158
PAX6 AACAGACACAGCCCTCACAAACA CGGGAACTTGAACTGGAACTGAC 274
Nestin CAGCTGGCGCACCTCAAGATG AGGGAAGTTGGGCTCAGGACTGG 208
Musashi 1 AGCTTCCCTCTCCCTCATTC GAGACACCGGAGGATGGTAA 161
Cardiac markers
TNTT2 ATCCCCGATGGAGAGAGAGT TCTTCTTCTTTTCCCGCTCA 385
MLC2V GGTGCTGAAGGCTGATTACGTT TATTGGAACATGGCCTCTGGAT 382
MLC2A GTCTTCCTCACGCTCTTTGG GCCCCTCATTCCTCTTTCTC 269
Cx-43 TACCATGCGACCAGTGGTGCGCT GAATTCTGGTTATCATCGGGGAA 293
MYH7 AGCTGGCCCAGCGGCTGCAGG CTCCATCTTCTCGGCCTCCAGCT 443
GATA4 GACGGGTCACTATCTGTGCAAC AGACATCGCACTGACTGAGAAC 474
HERG GAACGCGGTGCTGAAGGGCT AACTTGCGCTTGCGTTGCCG 527
Housekeeping control genes
-actin GTCTTCCCCTCCATCGTG GGGGTGTTGAAGGTCTCAAA 302
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Isoprenaline (Isuprel; Hospira, Lake Forest, IL), D,L-sotalol (Sigma),
erythromycin (Abbott, IL), cisapride (Sigma) and E-4031 (Alomone
Labs, Jerusalem, Israel) were diluted in 5% FBS containing EB
medium for drug tests. Baseline conditions as well as drug effects
were recorded for 2 minutes after a 2-minute stabilization period.
Baseline FPDs were measured from 43 control cardiomyocyte
aggregates and 30 LQT2 cardiomyocyte aggregates.
Statistical methods
Data are given as mean ± s.e.m. or s.d. Comparison of patch-clamp
data between LQT2-iPSC and control-iPSC cardiomyocytes was
performed using Student’s t-test for independent data. One-way
analysis of variance followed by Tukey test was used for comparison
of multiple groups. The IKr data was assessed using Student’s t-test
for independent data. The difference in FPDs between different
populations of spontaneously beating cardiomyocyte aggregates
was determined by nonlinear regression analysis using R software.
The difference in FPDs between populations when categorized
according to beating frequencies was determined by t-test with
SPSS software (IBM).
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TRANSLATIONAL IMPACT
Clinical issue
Long QT syndrome (LQTS) is a life-threatening cardiac disorder that
predisposes individuals to ventricular arrhythmias and sudden death. The
syndrome is characterized by a prolonged QT interval (detected by
electrocardiography) and can be caused either by genetic defects or as a side
effect of certain drugs. LQTS type 2 (LQT2) occurs owing to defective
functioning of the hERG potassium channel, and is caused by mutations in the
KCNH2 gene (also known as HERG). The drug-induced form of LQTS also occurs
owing to altered function of the hERG channel. Because prolongation of QT
interval is one of the most common severe side effects of both cardiac and
non-cardiac drugs, new drug candidates must be carefully tested for their
effects on the hERG channel. However, physiological human cell models to test
for this effect were not previously available. The clinical prevalence of LQTS is
only ~1:5000, but its genetic prevalence has been estimated to be much
higher (1:250 to 1:2000). Therefore, it is possible that asymptomatic carriers of
LQTS-associated mutations are more susceptible to the side effect of certain
medications, and are at risk of developing severe symptoms in certain settings. 
Results
This study investigates whether an LQTS-related phenotype can be detected in
an in vitro model based on cells from an asymptomatic carrier of an LQT2-
associated KCNH2 mutation. The authors generate patient-specific induced
pluripotent stem cells (iPSCs) from an asymptomatic individual and
differentiate them into functional cardiac cells. These cells recapitulate the
phenotypic characteristics of LQT2 in vitro, including prolonged repolarization
time and increased arrhythmogenicity. Additionally, at slow beating rates,
cardiomyocyte aggregates derived from these iPSCs present prolonged field
potential duration (QT) compared with control cells. These results are in line
with clinical findings that individuals with LQT2 usually display symptoms
when heart rate is slow. These results indicate that electrophysiological
abnormalities can be detected in iPSC-derived cardiac cells, even when
derived from asymptomatic carriers of KCNH2 mutations.
Implications and future directions
This in vitro model of LQT2 offers a new system with which to evaluate
electrophysiological properties and drug responses of cardiomyocytes from
KCNH2 mutation carriers with and without LQTS symptoms. In addition, the
model provides a platform from which to study the basic pathology of LQTS
and to identify genetic and non-genetic modifiers that can be considered in
designing and developing medications to treat distinct patient groups. In
addition, the model provides the means to analyze the cardiac side effects of
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